AVN 54.97 Decreased By ▼ -2.05 (-3.6%)
BOP 10.26 Increased By ▲ 0.13 (1.28%)
CHCC 128.48 Decreased By ▼ -0.35 (-0.27%)
DCL 9.06 Decreased By ▼ -0.26 (-2.79%)
DGKC 105.41 Decreased By ▼ -2.18 (-2.03%)
EFERT 66.81 Decreased By ▼ -0.69 (-1.02%)
EPCL 31.65 Decreased By ▼ -0.95 (-2.91%)
FCCL 21.12 Increased By ▲ 0.01 (0.05%)
FFL 13.15 Increased By ▲ 1.18 (9.86%)
HASCOL 13.63 Increased By ▲ 0.05 (0.37%)
HBL 129.25 Increased By ▲ 4.59 (3.68%)
HUBC 82.74 Increased By ▲ 1.34 (1.65%)
HUMNL 9.45 Decreased By ▼ -0.15 (-1.56%)
JSCL 15.52 Decreased By ▼ -0.33 (-2.08%)
KAPCO 24.38 Decreased By ▼ -0.38 (-1.54%)
KEL 3.63 Decreased By ▼ -0.08 (-2.16%)
LOTCHEM 12.93 Decreased By ▼ -0.27 (-2.05%)
MLCF 33.06 Decreased By ▼ -0.59 (-1.75%)
OGDC 113.77 Decreased By ▼ -0.74 (-0.65%)
PAEL 33.34 Increased By ▲ 0.59 (1.8%)
PIBTL 11.08 Decreased By ▼ -0.26 (-2.29%)
PIOC 80.43 Increased By ▲ 4.33 (5.69%)
POWER 8.76 Increased By ▲ 0.64 (7.88%)
PPL 99.48 Increased By ▲ 0.45 (0.45%)
PSO 184.86 Increased By ▲ 0.86 (0.47%)
SNGP 56.00 Decreased By ▼ -0.36 (-0.64%)
STPL 11.60 Increased By ▲ 0.39 (3.48%)
TRG 47.47 Decreased By ▼ -2.28 (-4.58%)
UNITY 12.54 Decreased By ▼ -0.02 (-0.16%)
WTL 0.98 Decreased By ▼ -0.03 (-2.97%)
BR100 4,110 Decreased By ▼ -26 (-0.64%)
BR30 20,962 Decreased By ▼ -197 (-0.93%)
KSE100 39,578 Decreased By ▼ -294 (-0.74%)
KSE30 17,158 Decreased By ▼ -163 (-0.94%)
COVID-19 TOTAL DAILY
CASES 280,461 432
DEATHS 5,999 15
Sindh 121,705 Cases
Punjab 93,336 Cases
Balochistan 11,777 Cases
Islamabad 15,095 Cases
KP 34,253 Cases

(Karachi) Coronavirus vaccine candidates will enter late-stage clinical studies by the end of the month, with others beginning in August, September and October, the U.S. government’s top infectious diseases expert said on Thursday.

The news comes as Moderna Inc, which is at the forefront of the country’s vaccine development efforts, reiterated earlier in the day that a late-stage trial with 30,000 volunteers would begin this month.

World's first inactivated Covid-19 vaccine produces antibodies: Chinese experts

“We may be able to at least know whether we are dealing with a safe and effective vaccine by the early winter, late winter, (or) beginning of 2021,” Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, said in an interview to JAMA Network.

According to the firm, volunteers who have undergone the phase II trial in May have shown positive early results, developing antibodies against the virus.

AstraZeneca, Moderna ahead in COVID-19 vaccine race: WHO

In June, China National Biotec Group (CNBG) announced that their inactivated COVID-19 vaccine had passed phase one and two clinical trials.

The vaccine showed no "serious adverse reactions" with all volunteers generating antibodies after two doses in 28 days, the company said.